Total immunotherapy for Hodgkin lymphoma - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Lancet Haematology Année : 2020

Total immunotherapy for Hodgkin lymphoma

Résumé

The anti-CD30 antibody-drug conjugate brentuximab vedotin and the programmed cell death 1 (PD-1) monoclonal antibodies nivolumab and pembrolizumab have dramatically improved outcomes for patients with relapsed or refractory classic Hodgkin lymphoma. With the goal of improving the depth and duration of remissions with these drugs, combination strategies investigating various combination partners are underway, including conventional chemotherapy and other checkpoint inhibitors. Trials investigating the combination of nivolumab and brentuximab vedotin in first and second-line settings showed a significant improvement in complete response rate compared with treatment with either nivolumab or brentuximab vedotin alone, suggesting the potential of this approach.
Fichier principal
Vignette du fichier
Houot_Total immunotherapy for Hodgkin lymphoma_accepted.pdf (151.7 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02930371 , version 1 (06-11-2020)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Roch Houot, Reid W. Merryman, Franck Morschhauser. Total immunotherapy for Hodgkin lymphoma. Lancet Haematology, 2020, 7 (9), pp.e629-e630. ⟨10.1016/S2352-3026(20)30220-9⟩. ⟨hal-02930371⟩
117 Consultations
174 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More